BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGEND001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGEND001\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07828353-1554@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:REGEND001: Phase 3 readout est. (NCT07828353)
DESCRIPTION:REGEND001\, phase 3\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Clinical Study of REGEND001 for the Treatment of Chronic Obstructi
 ve Pulmonary Disease (COPD)\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/regend001#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07828353
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987214-1554@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:REGEND001: Phase 1 readout est. (NCT06987214)
DESCRIPTION:REGEND001\, phase 1.\nStudy: REGEND001 Autologous Basal Layer S
 tem Cell Transplantation for Bronchiectasis: A Translational Application S
 tudy\nEstimated primary completion: 30 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/regend001#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06987214
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998706-1554@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:REGEND001: Phase 1 readout est. (NCT06998706)
DESCRIPTION:REGEND001\, phase 1.\nStudy: REGEND001 Autologous Basal Layer S
 tem Cell Transplantation for Interstitial Lung Disease (ILD): A Translatio
 nal Application Study\nEstimated primary completion: 30 June 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/regend001#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06998706
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946953-1554@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:REGEND001: Phase 1/2 readout est. (NCT06946953)
DESCRIPTION:REGEND001\, phase 1/2\, Chronic Obstructive Pulmonary Disease.\
 nStudy: REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chr
 onic Obstructive Pulmonary Disease (COPD): A Translational Application Stu
 dy\nEstimated primary completion: 31 December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/regend001#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06946953
URL:https://assetmemo.bio/drug/regend001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
